Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2075)	11/1/2000 9:45:12 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4974

Guess Nigel is asleep. He needs to get an assistant in the Americas......... Wednesday November 1, 7:30 pm Eastern Time Press Release SOURCE: Abgenix, Inc. Abgenix Announces $230 Million Private Placement FREMONT, Calif., Nov. 1 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX - news) announced today that it has entered into definitive purchase agreements for the sale of approximately 3.3 million shares of newly issued common stock to selected institutional and other accredited investors for approximately $230 million of gross proceeds. The purchase price is $70.00 per share. In addition, approximately 750,000 shares were sold by a selling stockholder, Cell Genesys, Inc. (Nasdaq: CEGE - news). After this financing, Cell Genesys will own approximately 10.5% of the outstanding stock of Abgenix. The shares of common stock have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration, or an applicable exemption from registration. Robertson Stephens served as the placement agent for this transaction. (snip) Amazing. The money spigot runs and runs.